-
Vignette-Based Economic Models in UK HTA Submissions: Valuable Tool or Just NICE in Theory?
Sep 9, 2025, 16:22 PM -
Intra-Procedure Cost Variability: A Retrospective Analysis of Real-World Patient Level Information Costing (PLICS) Data for a Minimally Invasive BPO Therapy in the NHS
Sep 9, 2025, 16:22 PM -
Mapping PBS Drug Pathways in Australia: A Framework and Interactive Tool for Category-Specific Pricing Calculations
Sep 9, 2025, 16:22 PM -
The Fiscal Case for Investing in COVID-19 Vaccination: A UK Treasury Perspective
Sep 9, 2025, 16:22 PM -
Clinical and Economic Impact of Early Treatment in Relapsing Remitting Multiple Sclerosis With High-Efficacy Disease-Modifying Therapy in Mexico
Sep 9, 2025, 16:22 PM -
Graphical Evidence Frameworks to Visualize the Holistic Value of Healthcare Interventions
Sep 9, 2025, 16:22 PM -
Social Media Listening Analysis of Cannabis Use in Patients With Inflammatory Bowel Disease
Sep 9, 2025, 16:22 PM -
Artificial Intelligence in Systematic Reviews: An Investigation Into the Impact of Eligible Studies Being Excluded by Artificial Intelligence
Sep 9, 2025, 16:22 PM -
Budget Impact Analysis Of Migalastat Incorporation vs. Enzyme Replacement Therapies For Fabry Disease: Validation of a Cost-Assessment Tool In Brazilian Private Healthcare System
Sep 9, 2025, 16:22 PM -
Disparities in Access to Gene Therapy in the European Union: Ethical and Regulatory Challenges
Sep 9, 2025, 16:22 PM -
Synthetic Data Generation Methods Using Artificial Intelligence (AI): A Simple New AI Tool That Generates Synthetic Data Using Generative Adversarial Network (CTGAN), Copula GANs, and Sequential Decision Tree Methods
Sep 9, 2025, 16:22 PM -
Evaluating the Annual Cost of Progression in CD30+ Cutaneous T-cell Lymphomas Following 2L+ Systemic Treatment in Italy
Sep 9, 2025, 16:22 PM -
Accelerating HEOR Using Petri Net-Based Simulation Informed by Real-World Data
Sep 9, 2025, 16:22 PM -
Facilitator-Led vs. Remote Components Within Structured Expert Elicitation of Survival Outcomes: A Targeted Review
Sep 9, 2025, 16:22 PM -
A Critical Review of the Screening Criteria Ratings and Recommendations by the UK National Screening Committee (NSC) for 30 Adult Conditions
Sep 9, 2025, 16:22 PM -
Current Use of Hereditary Angioedema (HAE) Treatments in Sweden: An Analysis of the National Prescribed Drug Register
Sep 9, 2025, 16:22 PM -
Humanistic and Financial Burden Experienced by Nonprofessional Care Partners of Patients With Mild Cognitive Impairment and Dementia Due to Alzheimer’s Disease: Results From a Real-World Survey in Spain
Sep 9, 2025, 16:22 PM -
Reframing Pharmaceutical Pricing: Implications of the 2025 SVR Report for Germany’s Pricing Logic and International Spillovers
Sep 9, 2025, 16:22 PM -
Danicopan in Addition to the Component 5 Inhibitor C5i Ravulizumab for the Treatment of Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Residual Hemolytic Anemia in Greece: A Cost Utility Analysis
Sep 9, 2025, 16:22 PM -
The Key Role of Social Participation in Health Technology Assessment: Experiences From South American Countries
Sep 9, 2025, 16:22 PM
